|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2003-5-26
|
|
pubmed:abstractText |
The current study was performed to assess whether sequential potentially noncross-resistant chemotherapy prolongs disease-free survival (DFS) and overall survival (OS) in patients with operable breast carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AmesFrederickF,
pubmed-author:AssikisVasilyV,
pubmed-author:BooserDanielD,
pubmed-author:BuzdarAmanA,
pubmed-author:HortobagyiGabrielG,
pubmed-author:SingletaryEvaE,
pubmed-author:SmithTerryT,
pubmed-author:TheriaultRichardR,
pubmed-author:ValeroVicenteV,
pubmed-author:WaltersRonaldR,
pubmed-author:YangYingY
|
|
pubmed:copyrightInfo |
Copyright 2003 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2716-23
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12767083-Antimetabolites, Antineoplastic,
pubmed-meshheading:12767083-Antineoplastic Agents,
pubmed-meshheading:12767083-Antineoplastic Agents, Alkylating,
pubmed-meshheading:12767083-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12767083-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12767083-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12767083-Breast Neoplasms,
pubmed-meshheading:12767083-Chemotherapy, Adjuvant,
pubmed-meshheading:12767083-Cyclophosphamide,
pubmed-meshheading:12767083-Disease-Free Survival,
pubmed-meshheading:12767083-Doxorubicin,
pubmed-meshheading:12767083-Female,
pubmed-meshheading:12767083-Fluorouracil,
pubmed-meshheading:12767083-Follow-Up Studies,
pubmed-meshheading:12767083-Humans,
pubmed-meshheading:12767083-Methotrexate,
pubmed-meshheading:12767083-Middle Aged,
pubmed-meshheading:12767083-Receptors, Estrogen,
pubmed-meshheading:12767083-Tamoxifen,
pubmed-meshheading:12767083-Vinblastine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
|
|
pubmed:affiliation |
Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
